Subtle Medical Receives Phase 2 Funding Approval to Enhance Imaging Technology
Subtle Medical, an AI-based medical imaging company, has received Phase 2 funding…
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Plozasiran reduced triglycerides by 80% from baseline and reduced the risk…
